Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Induction Nivolumab and Chemotherapy in Unresectable Stage III NSCLC
NCT06003075Phase 2Terminated
- Sponsor
- Ralph G. Zinner
- Start
- Dec 2023
- Primary completion
- Jul 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab in non-small cell lung cancer (NSCLC), sponsored by Ralph G. Zinner. Started Dec 2023; status: terminated.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06003075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06003075.